Patients with rectal cancer and a complete response (pCR) to chemoradiation have an excellent prognosis. Adjuvant chemotherapy is controversial and used only in a few cases. The results of the present study have demonstrated associations between survival and age, comorbidities, carcinoembryonic antigen, and chemotherapy use in this population. Thus, chemotherapy appears to be underused in the pCR setting. Background: In locally advanced rectal adenocarcinoma, 15% to 20% of patients treated with neoadjuvant chemoradiation (nCRT) achieve a pathologic complete response (pCR). The benefit of adjuvant chemotherapy is controversial in rectal cancer. Our objective was to evaluate the effect of clinical risk factors and adjuvant chemotherapy usage on the outcomes of the pCR patient population. Patients and Methods: We performed a retrospective study using the National Cancer Data Base from 2006 to 2013. The primary outcome was overall survival (OS). The association between OS and patient characteristics (demographics, tumor variables, and treatment) was examined using multivariable Cox regression modelling. Results: A total of 2891 patients were identified who had achieved a pCR. Of these 2891 patients, 2102 received nCRT and 789 received nCRT followed by adjuvant chemotherapy. The median follow-up duration was 43.2 months. The factors significantly associated with OS included age (P < .001), gender (P ¼ .011), Charlson-Deyo comorbidity score (P < .001), grade (P ¼ .029), clinical T stage (P ¼ .030), carcinoembryonic antigen negativity (P ¼ .002), and receipt of adjuvant chemotherapy (P < .001). Nodal status was not significantly associated with survival. The 5-year OS rate was 94% in the nCRT plus adjuvant group compared with 84% in the nCRT-alone group. Adjuvant chemotherapy was more likely to be given to younger patients (aged < 60 years), higher grade, lower Charlson-Deyo comorbidity score, elevated carcinoembryonic antigen level, higher clinical T stage, and higher clinical N stage. Conclusion: Our findings showed a significant improvement in OS for patients who received nCRT plus adjuvant chemotherapy compared with those who received nCRT alone. The nCRT plus adjuvant patients were more likely to be younger, have a lower comorbidity score, have clinical ! T3 disease, and have clinical node-positive disease. Thus, a selection bias could have been present. Nonetheless, even in the setting of already excellent outcomes, for patients with locally advanced rectal adenocarcinoma who achieve a pCR, the additional benefit of adjuvant chemotherapy should be weighed against the potential for toxicity.
Introduction
Colorectal cancer is the fourth most common malignancy in the United States, with an estimated 40,000 new cases of rectal cancer diagnosed in 2016 and a worrisome increase in incidence rates in the younger population. 1 The established treatment paradigm includes systemic chemotherapy, radiotherapy, and surgery for American Joint Committee on Cancer stage II and III rectal adenocarcinoma. 2 With the current treatment approach of preoperative chemoradiotherapy (CRT) and total mesorectal excision, the mortality and local recurrence rates have improved dramatically.
However, approximately one third of patients with locally advanced rectal cancer (LARC) will still subsequently develop distant metastases; thus, this is a major remaining problem for these patients. 3 The major potential method by which distant recurrence can be prevented after surgery is the use of adjuvant chemotherapy. The National Comprehensive Cancer Network guidelines have recommended consideration of adjuvant chemotherapy for patients who have received preoperative CRT. 4 Similarly, the European Society of Medical Oncology guidelines have advised that adjuvant chemotherapy should be given for pathologic stage III and "highrisk" stage II disease. 5 The definition of high risk differs slightly among the various expert groups but has generally included T4 tumor, poor differentiation, inadequate lymph node retrieval, perineural invasion (PNI), lymphovascular invasion (LVI), obstruction, and perforation. Elevated carcinoembryonic antigen (CEA) levels have also been linked to inferior outcomes. However, some debate remains regarding the applicability of these principles in clinical practice. Despite the widespread use of this approach, solid evidence to support the benefits of adjuvant chemotherapy after CRT and total mesorectal excision is lacking. 6 Among experts and general oncologists alike, debate continues regarding the need to include all 3 components of care (CRT, surgery, and chemotherapy) for every patient with LARC. Thus, in subgroups with a good prognosis, such as those patients achieving a pathologic complete response (pCR), it is defensible to argue against the routine inclusion of adjuvant chemotherapy, given the association with toxicity, expense, and effects on patient quality of life. The objective of the present study was to elucidate the patient-, tumor-, and treatment-related characteristics associated with overall survival (OS) in patients with LARC who achieved a pCR. As a major focus of interest, the receipt and effect of adjuvant chemotherapy were specifically assessed.
Patients and Methods

Patients
The National Cancer Data Base (NCDB), which captures approximately 70% of US cancer cases, was queried to identify patients from 2006 to 2013 with stage II-III rectal adenocarcinoma who had received neoadjuvant CRT (nCRT), followed by surgery. Documentation of several cancer-specific variables (eg, LVI, CEA, PNI) in the NCDB began at various points between 2004 and 2010; thus, the study period was chosen to allow inclusion of a large sample of rectal cancer patients with more comprehensive tumorrelated data available. For adenocarcinoma, the following "International Classification of Diseases for Oncology, third revision," codes were used: 8140-8145, 8150, 8210, 8211, 8220-8221, 8230, 8245, 8260-8263, 8310, 8480-8481, 8490.
Data were collected regarding patient, disease, and treatment variables. The patient variables included age, sex, race, ethnic origin, and Charlson-Deyo comorbidity index (CCI) score. The CCI is defined as an estimate of comorbid conditions according to the "International Classification of Diseases, ninth revision" diagnosis codes. Point values are assigned to indicate the severity of comorbid conditions. The NCDB truncates possible scores as 0, 1, and ! 2, because very few patients have a score > 2. Disease variables included year of diagnosis, tumor grade, tumor size, clinical TNM stage, pathologic TNM stage, number of lymph nodes examined, pretreatment CEA level, LVI, and PNI. The treatment variables included the surgical procedure and radiation and chemotherapy sequence (adjuvant or neoadjuvant, or both).
Statistical Analysis
The patient characteristics are reported stratified by chemotherapy status (neoadjuvant vs. adjuvant plus neoadjuvant) using the mean AE standard deviation for continuous variables and frequencies and relative frequencies for categorical variables. Comparisons were made using the Wilcoxon rank sum and Fisher's exact tests for continuous and categorical variables, respectively.
OS was summarized by chemotherapy status using standard Kaplan-Meier methods, with estimates of the median and 3-and 5-year survival rates obtained using 95% confidence intervals. Comparisons were made using the log-rank test. The association between chemotherapy status and OS was also examined within each demographic subgroup. Hazard ratios were obtained using Cox regression analysis and represented graphically using forest plots.
The association between OS and patient characteristics was examined using Cox regression models. Multivariable analysis was conducted using Cox regression, with all variables listed in Table 1 included in the model. All models were fit using Firth's method and the hazard ratios, with 95% confidence intervals, were obtained from the model estimates.
All analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC) at a significance level of P ¼ .05.
Results
Patient Characteristics
A total of 2891 patients who met the inclusion criteria were identified ( Figure 1) . Of the 2891 patients, 2102 received nCRT and 789 received nCRT plus adjuvant chemotherapy. The median age was 60 years. Most patients were white men (60%) with few or no comorbidities (CCI score of 0 for 79.8% and 1 for 16.4%). The tumors were predominantly moderately differentiated, and approximately one fourth were > 5 cm. The clinical stage was T3 in 80% of patients, with clinically involved lymph nodes in 44.2%. The patient characteristics are listed in Table 1 .
Significant differences were observed in multiple parameters between those who had received adjuvant chemotherapy and those who had not. These included age (P < .001), gender (P ¼ .030), CCI (P ¼ .027), year of diagnosis (P < .001), number of lymph nodes examined (P < .001), clinical T stage (P ¼ .025), clinical N stage (P < .001), and baseline CEA level (P ¼ .038). Comparing the differences, the mean age was slightly younger for those who received adjuvant chemotherapy than the age of those who had not (57 vs. 61 years). The adjuvant chemotherapy group had a greater 
Overall Survival
A significant difference in OS was found between the 2 patient cohorts (P < .001), with the patients who had received adjuvant chemotherapy experiencing better outcomes ( Figure 2 ). Many factors were significantly related to OS, including age (P < .001), gender (P ¼ .011), Hispanic origin (P ¼ .030), CCI (P < .001), grade (P ¼ .029), number of lymph nodes examined (P ¼ .002), clinical T stage (P ¼ .030), and CEA status (P ¼ .002). The patients with increased age, CCI score, grade, clinical T stage, and CEA positivity had poorer outcomes.
Multivariable Associations Between Patient Characteristics and OS
The multivariable analysis included all variables listed in Table 1 as covariates, except for LVI and PNI, owing to the extent of missing data. Because of the randomly missing data for other variables, the sample size for the multivariable model was only 953 patients. Age (P < .001), CCI (P ¼ .039), CEA status (P ¼ .006), and chemotherapy status (P ¼ .039) were significantly associated with survival (Table 2) . A trend toward an association with grade was found but the difference just missed significance (P ¼ .052).
OS Stratified by Adjuvant Chemotherapy
A significant difference was found in OS between the 2 chemotherapy cohorts (P < .001). The 5-year OS rate was 94% for the nCRT plus adjuvant group compared with 84% in the nCRT group. When adjusting for N stage, the nCRT plus adjuvant group retained superior OS, with 5-year OS rates for node-positive (Nþ) and node-negative (NÀ) disease of 94% and 95%, respectively. For nCRT alone, the 5-year OS rates for Nþ and NÀ disease were 86% and 83%, respectively. When stratified by the factors associated with the receipt of adjuvant chemotherapy, similar benefits were observed across the subgroups (Figure 3 ).
Discussion
The current practice standards for the treatment of stage II and III rectal adenocarcinoma generally consist of nCRT, followed by surgical resection. 2 The value of using additional measures for patients who achieve a pCR, specifically, the administration of adjuvant chemotherapy, is less clear. In this context, our study examined the largest pCR cohort that we are aware of to date. The data have demonstrated that in the context of a pCR to nCRT, the pretreatment factors of poorly differentiated histologic type, elevated CEA, and advanced T-stage tumor (in particular, T4) remain associated with worse outcomes. In contrast, clinical nodal status had no association with survival. These data suggest that chemotherapy has been used for only a few US patients with a pCR. Data presented as mean AE standard deviation or n (%). Abbreviations: CCI ¼ Charlson-Deyo comorbidity index; CEA ¼ carcinoembryonic antigen; LNs ¼ lymph nodes; LVI ¼ lymphovascular invasion; NOS ¼ not otherwise specified; PNI ¼ perineural invasion. a CCI score is an estimate of comorbid conditions using "International Classification of Diseases, ninth revision," diagnosis codes; a score of 0 indicates no comorbidities. Point values are assigned to indicate the severity of the comorbid conditions. The National Cancer Data Base truncates possible scores to 0, 1, and 2 owing to the small proportion of cases with a score of ! 2.
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Finally, but importantly, the data demonstrate an association between improved OS and the receipt of adjuvant chemotherapy. Adjuvant chemotherapy is routine for stage III colon cancer, with a fluoropyrimidine and oxaliplatin doublet serving as the standard because of a survival benefit demonstrated in randomized studies. 7 As previously noted, adjuvant chemotherapy for stage II and III rectal cancer is supported by guidelines; however, the data are inconsistent at best. This has led to controversy when considering the role of chemotherapy after nCRT. The European Organization for the Research and Treatment of Cancer 22921 trial randomized patients with clinical T3 and clinical T4 rectal cancer to neoadjuvant radiation versus CRT and adjuvant 5-fluorouracil (5-FU) versus observation. At 10 years of follow-up, no significant difference was found in survival. However, of the 506 patients randomized to adjuvant chemotherapy, only 369 (73%) began the course, 66% completed the course, and 43% received the full planned dose, potentially diluting the ability to detect a benefit.
Of relevance, the pathologic stage has proved to be a better predictor of outcomes than clinical stage. 8 The recent phase II study, ADORE, randomized 321 patients with pathologic stage II and III rectal cancer to adjuvant 5-FU/leucovorin (LV) versus FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin). 9 The 3-year disease-free survival was improved with FOLFOX (71.6% vs. 62.9%), suggesting a risk-adapted strategy might be appropriate in determining the use of adjuvant therapy for rectal cancer. The applicability to the present population in question is not direct, because that trial excluded ypT0-T2 disease. Furthermore, no observation-only cohort was included, precluding any conclusions regarding whether 5-FU/LV offers an advantage compared with observation alone. In summary, multiple factors have created uncertainty regarding the postoperative treatment of patients with an excellent response to preoperative therapy. The inconsistent data surrounding adjuvant therapy, the prognostic significance of preoperative staging compared with pathologic staging, and the perception of a lesser absolute benefit. Consistently, patients achieving a pCR after nCRT have excellent outcomes. In some studies, these outcomes were preserved regardless of the clinical stage: stage II versus III. 8 Other reports have suggested a worse outcome among patients with clinically Nþ disease before preoperative therapy. 10 Thus, from existing data, it has been unclear whether pretreatment factors such as nodal disease readmission was associated with decreased odds of the initiation of adjuvant therapy, as was increasing patient age. 11 Our study showed that patients who were younger and had fewer comorbidities were more likely to receive adjuvant therapy. Similar to our study, the Surveillance, Epidemiology, End Results data set also found that a more recent year of diagnosis was also associated with greater odds of the initiation of adjuvant therapy.
11
Previous reports have characterized the factors associated with the achievement of a pCR. Factors such as lower tumor grade, lower clinical T and N stage, and delaying surgery by > 6 to 8 weeks after the end of radiation have been shown to increase the likelihood of pCR, and the lack of health insurance was shown to lower the likelihood of a pCR. 12 Our study took these findings one step further and examined the factors for recurrence in the group of patients with a pCR, including their OS relative to the receipt of adjuvant chemotherapy. The present data demonstrated that although adjuvant chemotherapy was not commonly used, when a provider identified such patients and administered adjuvant therapy, these patients had a greater likelihood of survival. Although the group of patients who received adjuvant chemotherapy was younger and had no comorbidities, as denoted by the CCI, the difference was minimal numerically. Furthermore, in the subgroup analysis, the benefit of chemotherapy persisted across age groups and CCI scores. Thus, although we would hesitate to state that this proves a benefit for adjuvant chemotherapy and must acknowledge the inherent biases, at a minimum, these findings suggest that adjuvant chemotherapy is likely underused in this setting.
The advantages of the present study were that we used the NCDB database, which incorporates 70% of the nation's cancer cases. We had a large cohort of patients, allowing for a robust statistical analysis. To the best of our knowledge, ours is the largest dedicated analysis of patients with rectal cancer achieving a pCR. We acknowledge that the present study had important limitations. Given that the database included patients up to 2013, this limited the follow-up duration for more recently treated patients who are likely to receive modern regimens. The NCDB does not include recurrence information; thus, only OS, and not disease-free survival, could be calculated. Survival could have been potentially confounded by other patient-related factors that might not have been captured adequately in the database and that could not ever be fully accounted for through any adjusted analysis. Most importantly, some degree of additional bias is highly likely, which is inherent in observational data sets such as these. Younger, healthier patients were more likely to receive adjuvant chemotherapy, supporting the notion that the omission of adjuvant chemotherapy is a surrogate for older age and increased comorbidities, both risk factors for mortality. Supporting this, the observational population had a 5-year survival of < 85%. This is significantly inferior to that expected from previous trial data and observational cohorts, with estimated 5-year survival rates closer to 90% to 93%. 10, 13 Thus, because we could not capture the disease recurrence and disease-related mortality rates from this data set, the survival data could have been substantially skewed by a disproportionate number of deaths from nonecancer-related conditions. This is likely to be particularly true among the more elderly and infirm patients, for whom the treating provider opts not to administer additional chemotherapy. However, in the subgroup analysis, the benefit of adjuvant therapy was maintained across age groups, CCI scores, and year of diagnosis (2006-2009 vs. 2010-2012) . Additional limitations of note included a lack of data surrounding the chemotherapy regimens used, missing data, and the potential for errors in data recording. Furthermore, the modality of clinical staging was not reported. Compared with endoscopic ultrasonography, high-resolution rectal magnetic resonance imaging appears to be highly useful in the prediction of circumferential resection margin involvement, which has been strongly linked to the long-term outcomes and to have improved capability to predict nodal involvement, using imaging characteristics in addition to size alone. 14, 15 Thus, evolving imaging techniques might alter the staging and results of future studies. Nonetheless, the present study has provided useful information to help guide treatment decision making for patients with pCR after nCRT for rectal adenocarcinoma. We believe these data highlight the underuse of adjuvant chemotherapy in rectal cancer. Furthermore, the data lend support to more routine incorporation of adjuvant chemotherapy, even after achievement of a pCR. The optimal regimen to be used cannot be ascertained from the present data set. In addition, although 4 months of therapy has been commonly used in rectal cancer trials, the optimal duration is unknown-the ongoing international colon cancer collaboration, IDEA (International Duration Evaluation of Adjuvant Chemotherapy), is comparing 3 months of adjuvant therapy against 6 months. Should 3 months demonstrate non-inferiority, one might also consider the use of a shorter course of adjuvant therapy for rectal cancer. However, it is difficult to imagine universal comfort with only 1 month of therapy; thus, although a reduction from 4 months to 3 months might be plausible, a more abridged standard would seem unlikely, in particular, if oxaliplatin were used. Because it is highly unlikely that a randomized study will be conducted in this setting, database analyses such as ours and meta-analyses of clinical trials will likely remain the best methods to provide the evidence to support clinical decision making.
Conclusion
Our findings have demonstrated a significant improvement in OS for patients who received adjuvant chemotherapy compared with CRT and surgery alone. The patients receiving adjuvant chemotherapy were more likely to be younger, have a lower CCI score, have clinical T3 disease, and have clinical Nþ disease. Thus, a selection bias might have been present. Nonetheless, after achievement of a pCR through preoperative therapy, the additional benefit of adjuvant chemotherapy should be weighed carefully against the attendant toxicities. At present, adjuvant chemotherapy is likely underused.
Clinical Practice Points
Achievement of a pCR after nCRT is a good prognostic indicator in rectal cancer. The role of adjuvant chemotherapy is controversial in general and perhaps even more so in the setting of rectal cancer. The NCDB (2006-2013) was examined to delineate the risk factors for recurrence and assess the benefit of administering adjuvant chemotherapy. A total of 2891 patients were identified who achieved a pCR of the 34,508 with rectal adenocarcinoma who had undergone nCRT and radical resection. We found that age, gender, ethnicity, comorbidity index, histologic grade, lymph nodes examined, clinical T stage, and CEA were associated with survival on univariate analysis. On multivariate analysis, advanced age, higher CCI score, and elevated CEA were linked to worse outcomes, and adjuvant chemotherapy was linked to better outcomes. The benefit of adjuvant chemotherapy was maintained across all subgroups examined; however, a vast minority of patients received adjuvant chemotherapy.
Thus, even after achievement of a pCR, the use of adjuvant chemotherapy might improve the long-term outcomes for patients with rectal cancer. Adjuvant chemotherapy remains underused at present.
